HUS ParisMode de compatibilité]

First Page		Document Content
Date: 2016-05-16 12:27:10 Complement system Blood disorders Eculizumab Immunosuppressants Acquired hemolytic anemia Atypical hemolytic uremic syndrome Thrombotic microangiopathy TMA C5-convertase Nephrology Dialysis Factor H		HUS ParisMode de compatibilité] Add to Reading List Source URL: www.hemapherese.fr Download Document from Source Website File Size: 3,19 MB Share Document on Facebook

	Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris DocID: 1pPKn - View Document
	HUS ParisMode de compatibilité] DocID: 1oXIv - View Document
	1 INTERIM FUNDING CRITERIA IN ONTARIO FOR SOLIRIS AHUS –CASE BY CASE BASIS Initiation Criteria A patient must meet all three of the following to obtain funding for initial treatment of eculizumab for aHUS: 1. Confirmed DocID: 19QJ8 - View Document
	Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise wi DocID: 19nD4 - View Document
	PDF Document DocID: 16wNC - View Document